posted on 2021-03-09, 04:39authored bySaskia Ricks, Emily A. Kendall, David W. Dowdy, Jilian A. Sacks, Samuel G. Schumacher, Nimalan Arinaminpathy
Additional file 6: Figure S3. Relative value of Ag-RDT-led vs NAT-based testing, for averting infections in a hospital setting. The figure shows the same results as those presented in Fig. 3 in the main text, but here assuming that all patients awaiting a NAT result (whether as part of a NAT-based strategy or for confirmation of Ag-RDT results) were not isolated during this time. In panel (A), in the scenario where there was no NAT confirmation of Ag-RDT results (yellow points), 93% of simulations placed the Ag-RDT-led strategy in the favourable region, to the right of the vertical, dashed line. Panels (B, C) show additional sensitivity analyses for these points in particular, as described in Fig. 3. In (C), red lines show a NAT turnaround time of 3 days (vertical line), and a 30% NAT availability (horizontal line). In the upper right quadrant of these lines, an Ag-RDT was favourable over NAT in 69% of simulations.
Funding
Foundation for Innovative New Diagnostics Wellcome Trust UK Medical Research Council Department for International Development, UK Government